Research Article
The Effect of Prucalopride on Small Bowel Transit Time in Hospitalized Patients Undergoing Capsule Endoscopy
Table 1
Baseline characteristics of study population, the prucalopride versus the control group.
| Patient characteristic | Prucalopride
| Control
| value |
| Age mean, year (SD) | 64.4 (13.9) | 65.2 (16.4) | 0.85 | Male | 20 (68.9%) | 15 (60%) | 0.49 | Indication | | | 1 | Overt OGIB | 26 (89.6%) | 23 (92%) | | Occult OGIB | 1 (3.4%) | 1 (4%) | | Abnormal radiology | 2 (6.8%) | 1 (4%) | | Medical comorbidities | | | | Cardiac disease | 11 (37.9%) | 12 (48%) | 0.52 | Congestive heart failure | 5 (17.2%) | 7 (28%) | 0.37 | Valvular heart disease | 8 (27.5%) | 5 (20%) | 0.46 | Cerebrovascular disease | 3 (10.3%) | 5 (20%) | 0.45 | Chronic kidney disease | 4 (13.7%) | 1 (4%) | 0.35 | Chronic lung disease | 2 (6.8%) | 2 (8%) | 1 | Liver cirrhosis | 3 (10.3%) | 0 (0%) | 0.23 | Diabetes | 8 (27.5%) | 7 (28%) | 0.97 | Antiplatelets (ASA and/or plavix) | 11 (37.9%) | 7 (28%) | 0.44 | NSAIDS | 2 (6.8%) | 2 (8%) | 1 | Anticoagulants | 6 (20.6%) | 5 (20%) | 0.95 | Narcotics | 3 (10.3%) | 1 (4%) | 0.61 |
|
|
SD, standard deviation; OGIB, obscure gastrointestinal bleeding; NSAIDS, nonsteroidal anti-inflammatory drugs.
|